Cidara Therapeutics (CDTX) discloses 7,290-share RSU tax withholding

Rhea-AI Filing Summary

Cidara Therapeutics’ Chief Financial Officer reported a change in ownership of company common stock. On December 10, 2025, a transaction coded “F” involved 7,290 shares of common stock at $219.6 per share, identified as shares withheld to satisfy taxes upon RSU vesting.

Following this transaction, the officer directly owned 50,562 shares of Cidara Therapeutics common stock. This amount includes 352 shares acquired through the company’s Employee Stock Purchase Plan on November 20, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KARBE FRANK

(Last) (First) (Middle)

6310 NANCY RIDGE DRIVE

SUITE 101

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		F		7,290(1)	D	$219.6	50,562(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for taxes on RSU vesting.

2. Includes 352 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on November 20, 2025.

Remarks:

	/s/ Shane Ward, Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity transaction did Cidara Therapeutics (CDTX) report for its Chief Financial Officer?

The filing shows a December 10, 2025 transaction in which 7,290 shares of Cidara Therapeutics common stock were disposed of in a code “F” transaction, described as shares withheld for taxes on RSU vesting.

How many Cidara Therapeutics (CDTX) shares does the reporting officer own after the transaction?

After the reported transaction, the officer directly owns 50,562 shares of Cidara Therapeutics common stock.

What does the Form 4 say about the 7,290 Cidara Therapeutics (CDTX) shares involved in the transaction?

The explanation states that the 7,290 shares were withheld for taxes on RSU vesting, corresponding to a code “F” transaction.

Does the reported Cidara Therapeutics (CDTX) ownership include Employee Stock Purchase Plan shares?

Yes. The reported 50,562 shares of beneficial ownership include 352 shares acquired under the issuer’s Employee Stock Purchase Plan on November 20, 2025.

What is the earliest transaction date disclosed in this Cidara Therapeutics (CDTX) Form 4?

The earliest transaction date disclosed is December 10, 2025, which is shown both as the transaction date in Table I and as the Date of Earliest Transaction.